for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Catabasis Pharmaceuticals Inc

CATB.OQ

Latest Trade

6.00USD

Change

-0.05(-0.83%)

Volume

63,967

Today's Range

5.99

 - 

6.33

52 Week Range

3.60

 - 

9.76

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.05
Open
6.07
Volume
63,967
3M AVG Volume
0.93
Today's High
6.33
Today's Low
5.99
52 Week High
9.76
52 Week Low
3.60
Shares Out (MIL)
11.62
Market Cap (MIL)
70.28
Forward P/E
-2.44
Dividend (Yield %)
--

Latest Developments

More

Catabasis Pharmaceuticals Inc Quarterly Loss Per Share $0.62

Catabasis Pharmaceuticals Reports Q2 Loss Per Share $0.62

Catabasis Pharmaceuticals Inc Qtrly Loss Per Share $0.62

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Catabasis Pharmaceuticals Inc

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry

Biotechnology & Drugs

Contact Info

1 Kendall Sq Ste B14202

+1.617.3491971

http://www.catabasis.com/

Executive Leadership

Kenneth M. Bate

Co-Chairman of the Board

Michael J. Ross

Co-Chairman of the Board

Jill C. Milne

President, Chief Executive Officer, Co-Founder, Director

Deirdre A. Cunnane

Senior Vice President, General Counsel, Treasurer

Andrew John Nichols

Chief Scientific Officer

Key Stats

1.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-22.200

2017

-12.600

2018

-5.120

2019(E)

-2.479
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-55.82
Return on Equity (TTM)
-50.13

Latest News

BRIEF-Catabasis Pharmaceuticals Reports Q1 Loss Per Share $0.29

* CATABASIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

BRIEF-Catabasis Pharmaceuticals Presents New Edasalonexent Data

* CATABASIS PHARMACEUTICALS PRESENTS NEW EDASALONEXENT DATA SHOWING SIGNIFICANTLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION AS MEASURED BY MRI THROUGH ONE YEAR OF TREATMENT

BRIEF-Catabasis Pharma Aligns Resources To Focus On Lead Program Edasalonexent

* CATABASIS PHARMACEUTICALS ALIGNS RESOURCES TO FOCUS ON LEAD PROGRAM EDASALONEXENT FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

BRIEF-Clarus Lifesciences II Lp Reports A 6.92 Pct Stake In Catabasis Pharmaceuticals As Of March 22

* CLARUS LIFESCIENCES II LP REPORTS A 6.92 PCT STAKE IN CATABASIS PHARMACEUTICALS INC AS OF MARCH 22 - SEC FILING

BRIEF-Catabasis Pharmaceuticals Reports Q4 Loss Per Share $0.24

* CATABASIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND REVIEWS BUSINESS PROGRESS

BRIEF-Corriente Advisors Reports 7.3 Pct Passive Stake In Catabasis Pharmaceuticals

* CORRIENTE ADVISORS LLC REPORTS 7.3 PERCENT PASSIVE STAKE IN CATABASIS PHARMACEUTICALS INC AS OF FEBRUARY 16, 2018 - SEC FILING Source text : (http://bit.ly/2CDqdMi) Further company coverage:

BRIEF-Catabasis Reports Edasalonexent Preserved Muscle Function And Substantially Slowed Duchenne Muscular Dystrophy Disease Progression

* CATABASIS PHARMACEUTICALS REPORTS EDASALONEXENT PRESERVED MUSCLE FUNCTION AND SUBSTANTIALLY SLOWED DUCHENNE MUSCULAR DYSTROPHY DISEASE PROGRESSION THROUGH MORE THAN ONE YEAR OF TREATMENT

BRIEF-Catabasis Pharmaceuticals reports third quarter financial results

* Catabasis Pharmaceuticals reports third quarter 2017 financial results and reviews business progress

BRIEF-Catabasis Pharmaceuticals reports positive results from phase 2 trial of medicine for progressive muscle degeneration disease

* Catabasis Pharmaceuticals reports positive results from open-label extension of phase 2 movedmd® trial evaluating Edasalonexent in duchenne muscular dystrophy and plans to initiate phase 3 clinical trial in first half 2018

BRIEF-Catabasis Pharmaceuticals Q2 loss per share $0.32

* Catabasis Pharmaceuticals reports second quarter 2017 financial results and reviews business progress

BRIEF-CATABASIS PHARMACEUTICALS ANNOUNCES POSITIVE PRECLINICAL DATA ON CAT-5571

* CATABASIS PHARMACEUTICALS INC - ANNOUNCES POSITIVE PRECLINICAL DATA ON CAT-5571, SUPPORTING ITS POTENTIAL AS AN ORAL TREATMENT FOR CYSTIC FIBROSIS

BRIEF-Catabasis Pharmaceuticals Q1 loss per share $0.41

* Catabasis pharmaceuticals reports first quarter 2017 financial results and reviews business progress

BRIEF-Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent

* Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent in duchenne muscular dystrophy at the American Academy of Neurology 69th annual meeting

BRIEF-Catabasis Pharma Q4 loss per share $0.47

* Catabasis pharmaceuticals reports fourth quarter and full year 2016 financial results and recent corporate highlights

BRIEF-Astrazeneca Plc reports a 4.5 percent passive stake in Catabasis Pharmaceuticals as of February 3, 2017

* Astrazeneca Plc reports a 4.5 percent passive stake in Catabasis Pharmaceuticals as of February 3, 2017 - SEC filing Source text : [ID:http://bit.ly/2lyYl4w] Further company coverage:

BRIEF-Catabasis Pharmaceuticals announces top-line results for Part B of the MoveDMD trial for its experimental muscle-wasting disorder drug, Edasalonexent

* Catabasis Pharmaceuticals announces top-line results for Part B of the MoveDMD trial for edasalonexent (CAT-1004) in duchenne muscular dystrophy

BRIEF-Catabasis Pharmaceuticals reports publication of phase 1 data on edasalonexent in adult subjects

* Announced publication of phase 1 data on edasalonexent in adult subjects

BRIEF-Catabasis Pharma provides edasalonexent and rare disease pipeline updates at investor day

* Catabasis Pharma- Top-line safety and efficacy results from placebo-controlled portion of movedmd phase 2 trial are expected in first half of Q1 2017

BRIEF-Catabasis Pharmaceuticals Q3 loss per share of $0.54

* Catabasis Pharmaceuticals - expect cash, cash equivalents at Sept 30, 2016 to fund operating expenses, capital expenditure requirements through at least Sept 30, 2017

BRIEF-Catabasis completes target enrollment for part B of the MoveDMD trial

* Completes target enrollment for part B Of The MoveDMD trial, a phase 2 trial of Edasalonexent (CAT-1004) for the potential treatment of duchenne muscular dystrophy

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up